Please wait a minute...
文章检索
预防医学  2022, Vol. 34 Issue (8): 757-759    DOI: 10.19485/j.cnki.issn2096-5087.2022.08.001
  专家论坛 本期目录 | 过刊浏览 | 高级检索 |
浙江省防范输入性猴痘疫情的对策建议
林君芬
浙江省疾病预防控制中心公共卫生监测与业务指导所,浙江 杭州 310051
Countermeasures against imported monkeypox epidemic in Zhejiang Province
LIN Junfen
Department of Public Health Surveillance and Advisory, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China
全文: PDF(828 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 2022年5月以来,在中非和西非以外的40多个非地方性流行国家报告了猴痘实验室确诊病例,且已出现人际传播,疫情区域有不断扩大的趋势。本文介绍猴痘病毒特性,分析全球猴痘疫情流行态势和浙江省猴痘疫情输入风险,提出加强入境人员检疫、建立猴痘监测网络、开展健康教育、做好风险研判和各项应急准备等猴痘疫情防范对策建议。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
林君芬
关键词 猴痘监测防控措施浙江省    
Abstract:Since May 2022, laboratory-confirmed cases of monkeypox have been reported in more than 40 non-endemic countries and the epidemic may spread to other countries through human-to-human transmission. This study aims to introduce the characteristics of monkeypox virus and analyze the epidemic situation and the risk of imported cases in Zhejiang Province. Multiple recommendations are proposed to prevent monkeypox epidemics in Zhejiang Province including strengthening entry personnel quarantine, establishing monkeypox monitoring system, carrying out monkeypox-related health education, and making risk assessment and preparation.
Key wordsmonkeypox    surveillance    control strategy    Zhejiang Province
收稿日期: 2022-07-05      修回日期: 2022-07-26      出版日期: 2022-08-10
中图分类号:  R373.1  
基金资助:浙江省重点研发计划项目(2021C03038)
作者简介: 林君芬,主任医师,浙江省疾病预防控制中心公共卫生监测首席专家。主要从事公共卫生监测与预警预测、突发事件公共卫生风险评估、突发应急事件现场处置等疾病预防控制及相关研究工作。现任浙江省疾病预防控制中心公共卫生监测与业务指导所所长,兼任浙江省预防医学会理事、浙江省健康促进与教育协会常务理事、公共卫生监测专委会主任委员、医共体专委会主任委员、社区专委会主任委员等。主持参与多项浙江省重点研发计划项目、浙江省自然科学基金重点项目和国家自然科学基金等项目。获浙江省科技进步奖等各类奖项8项;近5年发表学术论文30多篇,主编(副主编)出版著作6部。
引用本文:   
林君芬. 浙江省防范输入性猴痘疫情的对策建议[J]. 预防医学, 2022, 34(8): 757-759.
LIN Junfen. Countermeasures against imported monkeypox epidemic in Zhejiang Province. Preventive Medicine, 2022, 34(8): 757-759.
链接本文:  
https://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2022.08.001      或      https://www.zjyfyxzz.com/CN/Y2022/V34/I8/757
[1] KUGELMAN J R,JOHNSTON S C,MULEMBAKANI P M,et al.Genomic variability of monkeypox virus among humans,Democratic Republic of the Congo[J].Emer Infec Dis,2014,20(2):232-239.
[2] HALANI S,MISHRA S,BOGOCH I I.The monkeypox virus[J/OL].CMAJ,2022,194(24)[2022-07-26].https://doi.org/10.1503/cmaj.220795.
[3] ALAKUNLE E,MOENS U,NCHINDA G,et al.Monkeypox virus in Nigeria:infection biology,epidemiology,and evolution[J/OL].Viruses,2020,12(11)[2022-07-26].https://doi.org/10.3390/v12111257.
[4] BUNGE E M,HOET B,CHEN L,et al.The changing epidemiology of human monkeypox-a potential threat? A systematic review[J/OL].PLoS Negl Trop Dis,2022,16(2)[2022-07-26].https://doi.org/10.1371/journal.pntd.0010141.
[5] SAXENA S K,ANSARI S,MAURYA V K,et al.Re-emerging human monkeypox:a major public-health debacle[J/OL].J Med Virol,2022[2022-07-26].https://doi.org/10.1002/jmv.27902.
[6] Centers for Disease Control and Prevention(CDC).Human monkeypox-Kasai Oriental,Democratic Republic of Congo,February 1996-October 1997[J].MMWR,1997,46(49):1168-1171.
[7] DESSEV G,IOVCHEVA-DESSEV C,BISCHOFF J R,et al.A complex containing p34cdc2 and cyclin B phosphorylates the nuclear lamin and disassembles nuclei of clam oocytes in vitro[J].J Cell Biol,1991,112(4):523-533.
[8] BROWN K,LEGGAT P A.Human monkeypox:current state of knowledge and implications for the future[J/OL].Trop Med Infect Dis,2016[2022-07-26].https://doi.org/10.3390/tropicalmed1010008.
[9] PETERSEN E,ABUBAKAR I,IHEKWEAZU C,et al.Monkeypox-enhancing public health preparedness for an emerging lethal human zoonotic epidemic threat in the wake of the smallpox post-eradication era[J].Int J Infect Dis,2019,78:78-84.
[10] PETERSEN B W,KABAMBA J,MCCOLLUM A M,et al.Vaccinating against monkeypox in the Democratic Republic of the Congo[J].Antiviral Res,2019,62:171-177.
[11] GRANT R,NGUYEN L L,BREBAN R.Modelling human-to-human transmission of monkeypox[J].Bull World Health Organ,2020,98(9):638-640.
[12] PETER O J,KUMAR S,KUMARI N,et al.Transmission dynamics of monkeypox virus:a mathematical modelling approach[J/OL].Model Earth Syst Environ,2021,15[2022-07-26].https://doi.org/10.1007/s40808-021-01313-2.
[13] BREMAN J G,KALISA R,STENIOWSKI M V,et al.Human monkeypox,1970-79[J].Bull World Health Organ,1980,58(2):165-182.
[14] REYNOLDS M G,WAUQUIER N,LI Y,et al.Human monkeypox in Sierra Leone after 44-year absence of reported cases[J].Emerg Infect Dis,2019,25(5):1023-1025.
[15] MAHASE E.Seven monkeypox cases are confirmed in England[J/OL].BMJ,2022,17 [2022-07-26].https://doi.org/10.1136/bmj.o1239.
[16] MAHASE E.Monkeypox:what do we know about the outbreaks in Europe and North America?[J/OL].BMJ,2022,20[2022-07-26].https://doi.org/10.1136/bmj.o1274.
[17] ANTINORI A,MAZZOTTA V,VITA S,et al.Epidemiological,clinical and virological characteristics of four cases of monkeypox support transmission through Sexual contact,Italy,May2022[J/OL].Euro Surveill,2022,27(22)[2022-07-26].https://doi.org/10.2807/1560-7917.ES.2022.27.22.2200421.
[18] MAHASE E.Monkeypox:gay and bisexual men with high exposure risk will be offered vaccine in England[J/OL].BMJ,2022,22[2022-07-26].https://doi.org/10.1136/bmj.o1542.
[19] KOZLOV M.Monkeypox goes global:why scientists are on alert[J].Nature,2022,606(7912):15-16.
[20] 林君芬,吴梦娜,吴昊澄,等.浙江省新型冠状病毒肺炎病例流行特征分析[J].预防医学,2020,32(3):217-222.
LIN J F,WU M N,WU H C,et al.Epidemiological characteristics of coronavirus disease 2019 in Zhejiang Province[J].Prev Med,2020,32(3):217-222.
[21] 戚小华,刘碧瑶,王臻,等.浙江省境外输入新型冠状病毒肺炎病例特征[J].预防医学,2021,33(6):541-544.
QI X H,LIU B Y,WANG Z,et al.The characteristics of imported COVID-19 cases from abroad to Zhejiang Province[J].Prev Med,2021,33(6):541-544.
[22] 伊赫亚,李川,王芃,等.全球新型冠状病毒肺炎疫情与早期防控对策[J].预防医学,2020,32(4):325-329.
YI H Y,LI C,WANG P,et al.Recommendation on global prevention and control of coronavirus disease 2019 in the early stage[J].Prev Med,2020,32(4):325-329.
[1] 顾伟玲, 彭晗琪, 吕大兵, 富小飞, 亓云鹏, 谢亮, 向泽林. 2001—2024年嘉兴市血吸虫病和螺情监测结果分析[J]. 预防医学, 2025, 37(9): 897-902.
[2] 陈绍云, 曹思静, 霍泳琦, 谷超男, 严新凤, 于传宁. 龙华区伤害病例特征分析[J]. 预防医学, 2025, 37(9): 950-954,958.
[3] 刘珊, 张劲松, 张文利, 王贺, 朱文烨, 沙琨. 猴痘病原学和流行病学研究进展[J]. 预防医学, 2025, 37(8): 789-793,798.
[4] 孙强, 黄颖, 李小勇, 杨晨迎, 王思嘉. 2014—2023年宁波市老年伤害病例特征分析[J]. 预防医学, 2025, 37(8): 822-826,831.
[5] 孙玲, 刘元青, 刘新光, 张楠, 温婵, 郝建宗, 李梅. 河北省某儿童医院住院患儿多重耐药菌耐药性分析[J]. 预防医学, 2025, 37(6): 616-621.
[6] 黄阳梅, 沈旭娟, 谢董颖, 张琦, 郑子聪, 王勐. 小学生体重监测信息反馈干预的效果评价[J]. 预防医学, 2025, 37(6): 541-545.
[7] 余朝彦, 洪斌, 吴小军, 王年伟, 高燕, 王杨凤. 阿坝藏族羌族自治州工作场所重点职业病危害因素监测结果[J]. 预防医学, 2025, 37(12): 1277-1281.
[8] 杜灵彬, 邱雨, 李辉章, 李润华, 朱陈, 王乐, 裘燕飞. 2021年浙江省肿瘤登记地区恶性肿瘤发病和死亡特征分析[J]. 预防医学, 2025, 37(10): 973-978.
[9] 鲁琴宝, 吴昊澄, 吴晨, 傅天颖, 丁哲渊, 王心怡, 杨珂, 林君芬. 2023年浙江省突发公共卫生事件特征分析[J]. 预防医学, 2024, 36(6): 487-490.
[10] 许荣全, 杜哲群, 余鹏飞, 沈国初, 胡洁, 张阳春. 嘉兴市13价肺炎球菌多糖结合疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2024, 36(5): 420-422,427.
[11] 傅天颖, 吴昊澄, 鲁琴宝, 丁哲渊, 王心怡, 杨珂, 吴晨, 林君芬. 2023年浙江省法定传染病疫情分析[J]. 预防医学, 2024, 36(5): 369-373.
[12] 陆飞越, 姚凤燕, 沈智健, 郭林杰. 平湖市非细菌性呼吸道感染病原学监测结果[J]. 预防医学, 2024, 36(3): 239-242.
[13] 冯小丽, 罗诗丽, 李衡, 李志浩, 黄泓轩, 陈汉青. 盐田区3~18岁学生校园伤害特征[J]. 预防医学, 2024, 36(12): 1073-1077.
[14] 蒋卓婧, 黄泽民, 王吉玲, 陈金堃. 呼吸道感染肠道病毒D68型病例特征分析[J]. 预防医学, 2024, 36(1): 44-46.
[15] 李琳, 沈方力, 茅俭英, 尹纯礼, 朱三妹, 刘世友. 2013—2022年宝山区出生监测结果分析[J]. 预防医学, 2024, 36(1): 13-16.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed